RPL7L1 pseudogene 17 (RPL7L1P17)

RPL7L1 pseudogene 17 is a human pseudogene, meaning it resembles the functional ribosomal protein L7-like 1 (RPL7L1) gene but does not code for a functional protein[6][8]. Pseudogenes often arise from duplication or retrotransposition events and generally do not have known biological functions, do not act as primary therapeutic targets, and are not associated with specific disease mechanisms, drug interactions, or clinical biomarkers. There is no current evidence implicating RPL7L1P17 in any human disease or therapeutic context. Key considerations: - The gene is annotated specifically as a *pseudogene*, not an active ribosomal protein or enzyme, and there is no evidence for an expressed protein or direct involvement in disease or drug response[6][8]. - Pseudogenes are usually studied as reference loci for evolutionary analysis, gene regulation, or as non-coding RNAs in rare cases. There is no clinical or experimental evidence for RPL7L1P17 being used as a biomarker, target, or having any pharmacological relevance based on the current scientific literature or gene annotation databases[6][8]. - Data provided in common genomic and gene annotation resources (GeneCards, NCBI Gene) confirm its status as a **pseudogene** with no known functional or therapeutic relevance. If you intended to refer to the functional gene *RPL7L1* (ribosomal protein L7-like 1), rather than this pseudogene copy, please clarify. The functional RPL7L1 has roles in RNA binding and ribosome assembly and has been studied in certain cancer contexts, but *RPL7L1P17* is not itself a protein or drug target[5][6][8].

Other names

RPL7L1P17